

Edgar Filing: UNILEVER PLC - Form 6-K

UNILEVER PLC
Form 6-K
June 13, 2005

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of June, 2005

UNILEVER PLC
(Translation of registrant's name into English)

UNILEVER HOUSE, BLACKFRIARS, LONDON, ENGLAND
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F..X.. Form 40-F.....

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):_____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No .X..

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

Exhibit 99 attached hereto is incorporated herein by reference.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UNILEVER PLC

Edgar Filing: UNILEVER PLC - Form 6-K

/S/ S G WILLIAMS
By S G WILLIAMS
SECRETARY

Date: June 10, 2005

EXHIBIT INDEX

EXHIBIT NUMBER	EXHIBIT DESCRIPTION
99	Notice to London Stock Exchange dated 10 June 2005, Director Shareholding

Exhibit 99

SCHEDULE 11

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

1) Name of company
UNILEVER PLC

2) Name of director
ALL DIRECTORS IN COMMON WITH ALL EMPLOYEES OF UNILEVER PLC

3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest
SHARES HELD BY UNILEVER EMPLOYEE SHARE TRUST (JERSEY)

4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified)
GREENWOOD NOMINEES LIMITED ACCOUNT NO: 438308

5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s)
NO

6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary

i. EXERCISE OF SHARES/SAVE OPTIONS BY SCHEME PARTICIPANTS

Edgar Filing: UNILEVER PLC - Form 6-K

ii. EXERCISE OF EXECUTIVE OPTIONS BY SCHEME PARTICIPANTS

7) Number of shares/amount of stock acquired

N/A

8) Percentage of issued class

N/A

9) Number of shares/amount of stock disposed

i. a) 2,076

b) 878

ii. a) 24,885

b) 15,600

Total 43,439

10) Percentage of issued class
NEGLIGIBLE

11) Class of security
ORDINARY 1.4P SHARES

12) Price per share

i. a) 425.00p

b) 528.00p

ii. a) 478.00p

b) 428.75p

13) Date of transaction

7 & 8 June 2005

14) Date company informed

10 June 2005

15) Total holding following this notification

47,985,636

16) Total percentage holding of issued class following this notification

Edgar Filing: UNILEVER PLC - Form 6-K

1.648%

If a director has been granted options by the company please complete the following boxes

17) Date of grant
N/A

18) Period during which or date on which exercisable
N/A

19) Total amount paid (if any) for grant of the option
N/A

20) Description of shares or debentures involved: class, number
N/A

21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise
N/A

22) Total number of shares or debentures over which options held following this notification
N/A

23) Any additional information
N/A

24) Name of contact and telephone number for queries
JOANNE MCDONALD 020 7822 5860

25) Name and signature of authorised company official responsible for making this notification
ALISON DILLON - DEPUTY SECRETARY

26) Date of Notification

10 June 2005

d compound in endocrinology is sold in the U.S. and Europe to the IN VITRO fertilization market, and is in clinical testing for endometriosis, uterus myoma and enlarged prostate (BPH). A further seven clinical programs are underway with various compounds. In addition, AEterna owns 62% of Atrium Biotechnologies, a profitable and growing developer, distributor and marketer of active ingredients, fine chemicals, cosmetic and nutritional products with sales exceeding \$Cdn 100 million in 2002. AEterna and its entities have 270 employees in Canada and Europe. AEterna shares are listed on the Toronto Stock Exchange (AEL) and the NASDAQ National Market (AELA). News releases and additional information about AEterna are available on its Web site at www.aeterna.com. To find out more about the current Phase III trial in non-small cell lung cancer, call 1-888-349-3232. **SAFE HARBOR STATEMENT** This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of the business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the

Edgar Filing: UNILEVER PLC - Form 6-K

forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. -30- CANADA MEDIA RELATIONS INVESTOR RELATIONS Paul Burroughs Jacques Raymond Tel.: (418) 652-8525 ext. 406 Tel.: (418) 652-8525 ext. 360 Cell.: (418) 573-8982 Cell.: (514) 703-5654 Fax: (418) 577-7671 Fax: (418) 577-7671 E-mail: paul.burroughs@aeterna.com E-mail: jacques.raymond@aeterna.com USA GERMANY INVESTOR RELATIONS SALES & MARKETING Lippert/Heilshorn & Associates Dr.Mathias Pietras Kim Sutton Golodetz Tel.: +49 69 426023423 Tel: (212) 838-3777 Fax: +49 69 426023444 E-mail: kgolodetz@lhai.com E-mail: mathias.pietras@zentaris.de SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AETERNA LABORATORIES INC. Date: July 29, 2003 By: /s/Claude Vadboncoeur -----
----- Claude Vadboncoeur Vice President, Legal Affairs and Corporate Secretary